Safety and Efficacy of Disease-Modifying Anti-Rheumatic AgentsFocus on the Benefits and Risks of Etanercept

被引：0
|
作者：
Roy Fleischmann
Imran Iqbal
Pallavi Nandeshwar
Andres Quiceno
机构：
[1] Radiant Research-Dallas,
[2] University of Texas Southwestern Medical Center at Dallas,undefined
来源：
Drug Safety | 2002年 / 25卷
关键词：
Rheumatoid Arthritis; Methotrexate; Infliximab; Etanercept; Sulfasalazine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The traditional approach to the treatment of rheumatoid arthritis (RA) has been the use of nonsteroidal anti-inflammatory drugs usually in combination with a disease-modifying antirheumatic drug (DMARD) such as hydroxychloroquine, gold, sulfasalazine, methotrexate, leflunomide or cyclosporin. Each of these DMARDs has its own distinct toxicities but has also been shown to be effective in reducing signs and symptoms of disease and to some extent, reduce radiological progression.
引用
收藏
页码：173 / 197
页数：24
相关论文
共 50 条
  • [1] Safety and efficacy of disease-modifying anti-rheumatic agents - Focus on the benefits and risks of etanercept
    Fleischmann, R
    Iqbal, I
    Nandeshwar, P
    Quiceno, A
    [J]. DRUG SAFETY, 2002, 25 (03) : 173 - 197
  • [2] Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs
    Kobayashi, Daisuke
    Ito, Satoshi
    Takai, Chinatsu
    Hasegawa, Eriko
    Nomura, Yumi
    Otani, Hiroshi
    Abe, Asami
    Ishikawa, Hajime
    Murasawa, Akira
    Narita, Ichiei
    Nakazono, Kiyoshi
    [J]. MODERN RHEUMATOLOGY, 2018, 28 (04) : 599 - 605
  • [3] Pharmacogenetics of disease-modifying anti-rheumatic drugs
    Tanaka, E
    Taniguchi, A
    Urano, W
    Yamanaka, H
    Kamatani, N
    [J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2004, 18 (02): : 233 - 247
  • [4] Disease-modifying anti-rheumatic drugs - Cyclosporin
    Chaudhuri, K
    Torley, H
    Madhok, R
    [J]. BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (09): : 1016 - 1021
  • [5] GUIDELINE ON CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Galloway, James
    [J]. RHEUMATOLOGY, 2016, 55 : 14 - 14
  • [6] Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis
    Roy Fleischmann
    [J]. Clinical Rheumatology, 2021, 40 : 4369 - 4372
  • [7] Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis
    Fleischmann, Roy
    [J]. CLINICAL RHEUMATOLOGY, 2021, 40 (11) : 4369 - 4372
  • [8] COVID-19 and Disease-Modifying Anti-rheumatic Drugs
    Kristin M. D’Silva
    Zachary S. Wallace
    [J]. Current Rheumatology Reports, 2021, 23
  • [9] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    [J]. CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [10] COVID-19 and Disease-Modifying Anti-rheumatic Drugs
    D'Silva, Kristin M.
    Wallace, Zachary S.
    [J]. CURRENT RHEUMATOLOGY REPORTS, 2021, 23 (05)
12345